CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING (4CPS-152)


BACKGROUND

- Voriconazole is the primary treatment for invasive pulmonary aspergillosis.
- Antifungal nebulization involves advantages, but there are no commercial antifungal pharmaceutical presentations for nebulization.

AIMS AND OBJECTIVES

- Characterize a compounded voriconazole solution for nebulization.
- Describe its use in a cohort of patients.

RESULTS

Comercial product | pH    | Osmolarity (mOsm/kg) |
------------------|-------|----------------------|
Accord®           | 4.97  | 359                  |
Kern®             | 7     | 503                  |
Normon®           | 5     | 313                  |

Voriconazole solution physicochemical characteristics

The characteristics of the compounded voriconazole solution are adequate for nebulization.
- Comounded voriconazole solution is well tolerated and it is not absorbed to the systemic circulation.
- Nebulized voriconazole could be an interesting therapeutic option to treat pulmonary infections and/or colonizations.

CONCLUSIONS AND RELEVANCE

Patients' basal characteristics and nebulized voriconazole treatment description (CF: cystic fibrosis, LT: lung transplantation, ICU: intensive care unit, P-ICU: pediatric intensive care unit). * Pathogen was isolated from the graft transportation medium.